Biogen (BIIB) Other Non Operating Income (2009 - 2015)
Biogen (BIIB) recorded quarterly Other Non Operating Income of -$15.0 million in Q1 2015, down 70.88% quarter-over-quarter from -$8.8 million in Q4 2014, and down 167.56% on a YoY basis from $22.2 million in Q1 2014.
Biogen (BIIB) Other Non Operating Income (2009 - 2015) Analysis & Trends
Biogen's Other Non Operating Income history runs 7 years deep, the most recent figure standing at -$15.0 million for Q1 2015.
- In Q1 2015, Other Non Operating Income fell 167.56% year-over-year to -$15.0 million; the TTM figure through Mar 2015 stood at -$35.2 million (down 35.1% YoY), while the FY2016 annual figure was -$217.4 million, down 75.75% from the prior year.
- Other Non Operating Income was -$15.0 million for Q1 2015 at Biogen, down from -$8.8 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $15.1 million in Q1 2012 to a low of -$16.3 million in Q3 2014.
- Historically, Other Non Operating Income has averaged -$5.9 million across 5 years, with a median of -$5.6 million in 2014.
- The sharpest annual moves came in 2013 and 2014: Other Non Operating Income plunged 453.49% in 2013, then soared 146.61% in 2014.
- A 5-year view of Other Non Operating Income shows it stood at -$4.0 million in 2011, then sank by 259.68% to -$14.3 million in 2012, then jumped by 62.39% to -$5.4 million in 2013, then sank by 63.16% to -$8.8 million in 2014, then tumbled by 70.88% to -$15.0 million in 2015.
- The last three Other Non Operating Income figures came in at -$15.0 million (Q1 2015), -$8.8 million (Q4 2014), and -$16.3 million (Q3 2014), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | -14.99 Mn |
| Dec 31, 2014 | -8.77 Mn |
| Sep 30, 2014 | -16.29 Mn |
| Jun 30, 2014 | 4.86 Mn |
| Mar 31, 2014 | -5.60 Mn |
| Dec 31, 2013 | -5.38 Mn |
| Sep 30, 2013 | -4.64 Mn |
| Jun 30, 2013 | -10.43 Mn |
| Mar 31, 2013 | -14.46 Mn |
| Dec 31, 2012 | -14.29 Mn |
| Sep 30, 2012 | -4.55 Mn |
| Jun 30, 2012 | 2.95 Mn |
| Mar 31, 2012 | 15.14 Mn |
| Dec 31, 2011 | -3.97 Mn |
| Sep 30, 2011 | -7.73 Mn |
| Dec 31, 2010 | -4.70 Mn |
| Sep 30, 2010 | -6.90 Mn |
| Jun 30, 2010 | 1.00 Mn |
| Mar 31, 2010 | -8.40 Mn |
| Dec 31, 2009 | 6.40 Mn |